ReviewCNS neuroscience & therapeutics2021
The promise of exosome applications in treating central nervous system diseases.
Review in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- BMSC-Derived Exosomal miR-21a-5p Ameliorates Blood-Brain Barrier Injury and Hemorrhagic Transformation.Molecular neurobiology · 2026Article
- Advances in Intranasal Delivery of Exosomes for Central Nervous System Disorders.Molecular neurobiology · 2025Review
- Exosomes as Emerging Therapeutic Platforms in Neurological and Psychiatric Disorders.Pharmaceutical medicine · 2025Review
- Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2025Review
- Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies.Journal of nanobiotechnology · 2025Review
- LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review.Cellular and molecular neurobiology · 2025Review
- Exosomes-Based Nanotherapeutic Strategies: An Important Approach for Spinal Cord Injury Repair.International journal of nanomedicine · 2025Review
- The roles of extracellular vesicles in mental disorders: information carriers, biomarkers, therapeutic agents.Frontiers in pharmacology · 2025Review
- cGAS-STING signaling pathway in lung cancer: Regulation on antitumor immunity and application in immunotherapy.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Exosomes in Central Nervous System Diseases: A Comprehensive Review of Emerging Research and Clinical Frontiers.Biomolecules · 2024Review
- Review
- Neuroglobin-enriched secretome provides neuroprotection against hydrogen peroxide and mitochondrial toxin-induced cellular stress.Cell stress · 2024Article
- Circular RNAs: A New Approach to Multiple Sclerosis.Biomedicines · 2023Review
- Review
- Insights into Exosome Transport through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Neural stem/progenitor cell-derived extracellular vesicles: A novel therapy for neurological diseases and beyond.MedComm · 2023Review
- Compromised endothelial progenitor cell exosomal communication with endothelial cells in hypertension ischemia conditions.Frontiers in stroke · 2022Article
- Exosomal noncoding RNAs in central nervous system diseases: biological functions and potential clinical applications.Frontiers in molecular neuroscience · 2022Review
- The promise of exosome applications in treating central nervous system diseases.CNS neuroscience & therapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Exosomes (EXs), a type of extracellular vesicles, are secreted from virtually all types of cells. EXs serve as cell-to-cell communicators by conveying proteins and nucleic acids with regulatory functions. Increasing evidence shows that EXs are implicated in the pathogenesis of central nervous system (CNS) diseases. Moreover, EXs have recently been highlighted as a new promising therapeutic strategy for in vivo delivery of nucleotides and drugs. Studies have revealed that infusion of EXs elicits beneficial effects on the CNS injury animal models. As compared to cell-based therapy, EXs-based therapy for CNS diseases has unique advantages, opening a new path for neurological medicine. In this review, we summarized the current state of knowledge of EXs, the roles and applications of EXs as a viable pathological biomarker, and EX-based therapy for CNS diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.